Tumor Markers: A Short Overview
Recent advances in genomic technology, in particular gene expression profiling, may elucidate novel tumor markers or signatures that will predict how various tumors will behave and respond to various treatment modalities. In head and neck cancer, tumor markers may address current functional deficits in treating locally advanced disease. Progress in high-throughout techniques, will greatly promote identification and development of novel biomarkers that distinguish normal oral epithelia from potentially malignant lesions and early stage oral cancer. Further validation of these biomarkers and application in combination with routine histological studies will lead to improved diagnostic approaches and therapeutic strategies when the cancer is most curable.
Rizzolo D, Hanifin C, Chiodo TA. Oral cancer: How to find this hidden killer in two minutes. JAAPA. 2007;20(10):42-7.
Manzar W, Raghvan MRV, Aroor AR. Evaluation of serum β2-microglobulin in oral cancer. Aust Dent J. 1992;37(1):39-42.
Ayude D, Gacio G, Cadena MP. Combined use of established and novel tumor markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep. 2003;10:1345-50.
Schliephake.H: Prognostic relevance of molecular markers of oral cancer—A review. Int J Oral Maxillofac Surg. 2003;32:233–45.
Sanjay BR, Madhavi BR, Shyam NDVN. Tumour Markers in Oral Neoplasia. IJDA. 2010;2(1):103-14
Agrup M, Stal O, Oslen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Treat 2000;63:23-9.
Thomas GT, Lewis PM, Spieght MP.Mtraix metalloproteinase and oral cancer-review. Oral Oncol. 1999;35(3):227-33.
Sokoll LJ, Chan DW. Biomarkers for cancer diagnostics. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloof’s clinical oncology. Non-small cell lung cancer. 2011:23(3):122-5.
Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: Relevance to adverse pregnancy outcome. Exp Biol Med 2007;232(8):993-1004.
Drugan A, Weissman A, Evans MI. Screening for neural tube defects. Clin Perinatol. 2001;28:279–87.
Muller F. Prenatal biochemical screening for neural tube defects. Childs Nerv Syst. 2003;19:433-5.
Turriziani M, Fantini M, Benvenuto M, et al. Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials. Recent Pat Anticancer Drug Discov. 2012;5:25-27.
Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439–62.
Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Seminars in Cancer Biology 1999;9(2):67-81.
Frague P. Calcitonin's fantastic voyage: From hormone to marker of a genetic disorder. Gesnerus 2007;64(1-2):69-92.
Boss DS, Glen H, Beijnen JH, et al. Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori 2011;97(1):109-14.
Schliephake H. Prognostic relevance of molecular markers of oral cancer—A review. Int. J. Oral Maxillofac Surg. 2003;32:233-45.
Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol. 2004;15:1319-29.
Ivonine AMZ, Danial ADO, Wendy KDT, Ulrike K, Betnardo AVR, Cesar ARM. Nuleolar organizer regions in a chronic stress and oral cancer model. Oncol Lett. 2012;3(3):541-4.
Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010;107:163–224.
Whitfield JR, Soucek L. Tumor microenvironment; Becoming sick of Myc. Cell Mol Life Sci. 2012;69(6):931-4.
Baudino TA, McKay C, Pendeville-Samain H. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002;16:2530-43.
Lane DP. Cancer: p53, guardian of the genome. Nature 1992;358:15-6.
Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010;31:1501-8.
Zhao Z, Zuber J, Diaz-Flores E. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes De. 2010;24:1389-402.
Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91:179-84.
Miller LD, Smeds J, George J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005;102:13550-5.
Kochhar R, Howard EM, Umbreit JN, Lau SK. Metaplastic breast carcinoma with squamous differentiation: molecular and clinical analysis of six cases. Breast J. 2005;11:367-9.
Junttila MR, Karnezis AN, Garcia D. Selective activation of p53-mediated tumor suppression in high-grade tumors. Nature 2010;468:567-71.
Feldser DM, Kostova KK, Winslow MM. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010;468:572-5.
Muramatsu T, Muramatsu H, Kojima T. Identification of proteoglycan-binding proteins. Methods Enzymol. 2006;416:263–78.
Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nat. 2000;407:1029-34.
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.
Muramatsu T, Muramatsu H. Glycosaminoglycan-binding cytokines as tumor markers. Review. Proteomics 2008;8:3350-9.
Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 1997;3:647-51.
Kraft A, Weindel K, Ochs A, Marth C. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178–87.
Tang ZY, Ye SL, Liu YK, Qin LX. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187-96.
Guo RP, Zhong C, Shi M, Zhang CQ. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:547–55.
Iguchi H, Yokota M, Fukutomi M, Uchimura K. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2002;21:309–13.
Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003;63:3121–6.
Tamura M, Oda M, Matsumoto I, Tsunezuka Y. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol. 2004;11:928-33.
Imoto H, Osaki T, Taga S, Ohgami A. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg. 1998;115:1007-14.
Laack E, Kohler A, Kugler C, Dierlamm T. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol. 2002;13:1550-7.
Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79:144–6.
Tas F, Duranyildiz D, Oguz H, Camlica H. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006;24:492–6.
Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 200315;194(2):221-33.
Sherman M, Multhoff G. Heat Shock proteins in Cancer. Ann NY Acad Sci. 2007;1113:192-201.
Bellet D, Bidart JM. Biological markers of cancer. Critical study. Press Med. 199317;22(14):680-6.
Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 2006;11(5):385-405.
Ajay GN, Laxminath chatra. Tumor markers: An overview. J Indian Acad Oral Med Radiol. 2010;22(3):147-50.
McGee JO, Isaccson R, Wright GH (Eds). Oxford textbook of pathology. Oxford medical publication. Oxford: 1991. 345-9 p.
Werner JA, Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, Rudert H. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother. 1997;44(2):112-6.
Wolf P, Reid D. Use of Radiolabeled Antibodies for Localization of Neoplasms. Arch Intern Med. 1981;141(8):1067-70.
Harris L, Fritsche H, Mennel R. Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312.
Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx: J Am Soc Experiment Neuro Therapeutics. 2004;(1):182-8.
Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis 2000;21:517–24.
Canil CM, Tannock IF. Doctor’s dilemma: Incorporating tumor markers into clinical decision-making. Stem Oncol. 2002;29:286-93.
Chung CH, Parker JS, Karaca G. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5:489-500.
Cromer A, Carles A, Millon R. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 2004;23:2484-98.
Chin D, Boyle GM, Williams RM. Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005;113:789-97.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.
|Published by Celesta Software Pvt Ltd|